Dr. Reddy’s Laboratories Ltd. has launched Bupropion Hydrochloride Extended-Release Tablets, USP (XL) and Metaxalone Tablets which are approved by the U.S. Food & Drug Administration (USFDA).
Bupropion Hydrochloride Extended-Release Tablets, 150 mg and 300 mg, a therapeutic equivalent generic version of Wellbutrin XL® (Bupropion Hydrochloride Extended-Release) Tablets. And Metaxalone Tablets, USP 800 mg, a therapeutic equivalent generic version of Skelaxin® (metaxalone) Tablets.
The Skelaxin® brand and generic had U.S. sales of approximately $139 million MAT for the most recent twelve months ending in July 2017 according to IMS Health*. Dr. Reddy’s Metaxalone Tablets, USP 800 mg are available in the bottle count size of 100. Skelaxin® is a trademark of King Pharmaceuticals Research and Development, Inc.
The Wellbutrin XL® brand and generic had U.S. sales of approximately $754 million MAT for the most recent twelve months ending in July 2017 according to IMS Health*. Dr. Reddy’s Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg, are each available in bottle count sizes of 30, 90 and 500. Wellbutrin XL® is a trademark of GlaxoSmithKline LLC.
